SCHEMBL25758396

SCHEMBL25758396

CCCCOc1ccc(S(=O)(=O)NCCCN2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 7/20 0.73
ALDH1A1 P00352 5/20 0.64
KMT2A Q03164 2/20 0.64
POLB P06746 2/20 0.64
LMNA P02545 1/20 0.64
TSHR P16473 2/20 0.56
MMP1 P03956 1/20 0.56
MMP9 P14780 1/20 0.56
MMP13 P45452 1/20 0.56
ADAM17 P78536 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
MEN1 O00255 1/20 0.54
HTR1A P08908 2/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
RAB9A P51151 1/20 0.51
MBTD1 Q05BQ5 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24069402 0.86 TMEM97 (0.60) HTR7ALDH1A1KMT2ATSHRSMN1; SMN2
SCHEMBL13285873 0.84 HTR7 (0.56) HTR7ALDH1A1KMT2ATSHRMMP1
SCHEMBL24069058 0.83 HTR7 (0.85) HTR7ALDH1A1KMT2APOLBLMNA
SCHEMBL23648883 0.83 HTR7 (0.56) HTR7POLBMMP1MMP9MMP13
SCHEMBL23649331 0.82 KMT2A (0.67) HTR7ALDH1A1KMT2APOLBLMNA
SCHEMBL23648940 0.81 TMEM97 (0.58) ALDH1A1KMT2APOLBLMNATSHR
SCHEMBL25758369 0.80 HTR1A (0.68) HTR7HTR1AHTR2AHTR2C
SCHEMBL30375342 0.80 HTR1A (0.68) HTR7HTR1AHTR2AHTR2C
SCHEMBL24069061 0.80 HTR7 (1.00) HTR7ALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL24069103 0.79 HTR7 (0.49) HTR7KMT2ASMN1; SMN2MEN1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 CN claimed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 CN disclosed
EP-4159718-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 HTR7 79/4885ALDH1A1 1394/4885KMT2A 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.